| Ticker | ERAS |
|---|---|
| ISIN | US29479A1088 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-p...
El precio actual de Erasca, Inc. (ERAS) es de 21,49 , con una variación del -4,36%.
Erasca, Inc. opera en el sector Healthcare, industria Biotechnology.